Tempest Therapeutics, Inc. · Drugmakers

TPST

High riskNext report: Around Nov 4 (est.)

View price ↗

The short version

A company still losing money, with high risk. Institutions are adding.

Going well

Buying back shares: share count down 64% in 3 years

Watch out for

About 3 months of cash left at its current burn
Losing money, losses are large next to sales
4 offering filings in 6 months (may sell new shares)

Money moves

No insider buying or selling in the last 30 days
Institutions added 65% to their holdings in the quarter ending June 2026 (9 bought, 8 sold)

Facts from SEC filings, not a recommendation.

The business over time

Last 12 quarters, from SEC filings

Profit, Jun '26

-$5.2M

Sep '23Tap a barJun '26

Last 12 months: -$40.5M.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/4Weak

MissDebt under half of equityNot relying on borrowed money.0.63x equity
MissProfitable every yearSteady profits, not one good year.0 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$26.8M
PassShare count not growingNot diluting owners. Falling means buybacks.-64.1% in 3 years

Total debt: $4.2M; 0.63x equity
Current ratio: 2.50x; short-term assets / bills due
Free cash flow: -$26.8M

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, net margin 10%+, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 13

EPS: -$0.34; vs -$2.07
Free cash flow: -$2.8M
Share count: +300.3%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

28/ 100

This week: 1
Normal week: 2.5
vs normal: 0.4x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+64.5%

Institutions added 64.5% to their holdings. 9 bought, 8 sold.

Shares held by institutions1.3M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+147.4%

Cash runwayAt last year's cash burn

0 months

Debt to equityLatest balance sheet: debt compared with what owners have

Owes more than it owns

Shares outstandingLatest reported

15M

Why high risk

Losing money, losses are large next to sales
Less than a month of cash left at its current burn
Share count growing 147.4% a year (dilution)
Owes more than it owns (negative equity)
Bills due within a year exceed short-term assets
Revenue down 54.8% from the year before
9 offering filings in 6 months (may sell new shares)
Exchange listing notice (a delisting warning or a move to another exchange)

Earnings reports

Last 12

Next reportAround Nov 4 (est.)Estimated from the same quarter last year

Results filedAug 13
Results filedMay 14
Results filedMar 30
Results filedNov 5, 2025
Results filedAug 11, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

Proxy statementOct 26 · Form DEF 14A ↗Shareholder vote resultsOct 20 · Form 8-K ↗DEFA14AOct 20 · Form DEFA14A ↗Leadership changeOct 19 · Form 8-K ↗PRE 14AOct 16 · Form PRE 14A ↗DOct 14 · Form D ↗Offering prospectusOct 2 · Form 424B3 ↗New insiderOct 2 · Form 3 ↗

Stock awardNancy Freda SmithDirector

25,000 shares

Now owns 25,000 shares
Exercise price $1.00
Stock Option (right to buy)
Filed 10 days after trade

Sep 22Form 4 ↗

EFFECTOct 1 · Form EFFECT ↗Major agreementSep 28 · Form 8-K ↗Shelf offering registrationSep 25 · Form S-3 ↗Major agreementSep 17 · Form 8-K ↗Shareholder vote resultsSep 16 · Form 8-K ↗DEFA14ASep 16 · Form DEFA14A ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page